Cargando…

Nanomaterials in tumor immunotherapy: new strategies and challenges

Tumor immunotherapy exerts its anti-tumor effects by stimulating and enhancing immune responses of the body. It has become another important modality of anti-tumor therapy with significant clinical efficacy and advantages compared to chemotherapy, radiotherapy and targeted therapy. Although various...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Xudong, Li, Shenglong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10262535/
https://www.ncbi.nlm.nih.gov/pubmed/37312116
http://dx.doi.org/10.1186/s12943-023-01797-9
_version_ 1785058073572802560
author Zhu, Xudong
Li, Shenglong
author_facet Zhu, Xudong
Li, Shenglong
author_sort Zhu, Xudong
collection PubMed
description Tumor immunotherapy exerts its anti-tumor effects by stimulating and enhancing immune responses of the body. It has become another important modality of anti-tumor therapy with significant clinical efficacy and advantages compared to chemotherapy, radiotherapy and targeted therapy. Although various kinds of tumor immunotherapeutic drugs have emerged, the challenges faced in the delivery of these drugs, such as poor tumor permeability and low tumor cell uptake rate, had prevented their widespread application. Recently, nanomaterials had emerged as a means for treatment of different diseases due to their targeting properties, biocompatibility and functionalities. Moreover, nanomaterials possess various characteristics that overcome the defects of traditional tumor immunotherapy, such as large drug loading capacity, precise tumor targeting and easy modification, thus leading to their wide application in tumor immunotherapy. There are two main classes of novel nanoparticles mentioned in this review: organic (polymeric nanomaterials, liposomes and lipid nanoparticles) and inorganic (non-metallic nanomaterials and metallic nanomaterials). Besides, the fabrication method for nanoparticles, Nanoemulsions, was also introduced. In summary, this review article mainly discussed the research progress of tumor immunotherapy based on nanomaterials in the past few years and offers a theoretical basis for exploring novel tumor immunotherapy strategies in the future.
format Online
Article
Text
id pubmed-10262535
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-102625352023-06-15 Nanomaterials in tumor immunotherapy: new strategies and challenges Zhu, Xudong Li, Shenglong Mol Cancer Review Tumor immunotherapy exerts its anti-tumor effects by stimulating and enhancing immune responses of the body. It has become another important modality of anti-tumor therapy with significant clinical efficacy and advantages compared to chemotherapy, radiotherapy and targeted therapy. Although various kinds of tumor immunotherapeutic drugs have emerged, the challenges faced in the delivery of these drugs, such as poor tumor permeability and low tumor cell uptake rate, had prevented their widespread application. Recently, nanomaterials had emerged as a means for treatment of different diseases due to their targeting properties, biocompatibility and functionalities. Moreover, nanomaterials possess various characteristics that overcome the defects of traditional tumor immunotherapy, such as large drug loading capacity, precise tumor targeting and easy modification, thus leading to their wide application in tumor immunotherapy. There are two main classes of novel nanoparticles mentioned in this review: organic (polymeric nanomaterials, liposomes and lipid nanoparticles) and inorganic (non-metallic nanomaterials and metallic nanomaterials). Besides, the fabrication method for nanoparticles, Nanoemulsions, was also introduced. In summary, this review article mainly discussed the research progress of tumor immunotherapy based on nanomaterials in the past few years and offers a theoretical basis for exploring novel tumor immunotherapy strategies in the future. BioMed Central 2023-06-13 /pmc/articles/PMC10262535/ /pubmed/37312116 http://dx.doi.org/10.1186/s12943-023-01797-9 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Review
Zhu, Xudong
Li, Shenglong
Nanomaterials in tumor immunotherapy: new strategies and challenges
title Nanomaterials in tumor immunotherapy: new strategies and challenges
title_full Nanomaterials in tumor immunotherapy: new strategies and challenges
title_fullStr Nanomaterials in tumor immunotherapy: new strategies and challenges
title_full_unstemmed Nanomaterials in tumor immunotherapy: new strategies and challenges
title_short Nanomaterials in tumor immunotherapy: new strategies and challenges
title_sort nanomaterials in tumor immunotherapy: new strategies and challenges
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10262535/
https://www.ncbi.nlm.nih.gov/pubmed/37312116
http://dx.doi.org/10.1186/s12943-023-01797-9
work_keys_str_mv AT zhuxudong nanomaterialsintumorimmunotherapynewstrategiesandchallenges
AT lishenglong nanomaterialsintumorimmunotherapynewstrategiesandchallenges